Admitting that this subcohort may be biased toward a healthier population, we only included them so that their PSA measurements were available at 12 weeks (i.e., four cycles) after docetaxel initiation as defined by the Prostate Cancer Clinical Trials Working Group 3 [26]. Here, KLK3 is linked to prostate carcinoma.